UPDATE: Deutsche Bank Reiterates on Alexion Pharmaceuticals Ahead of Asfotase Alfa Launch
In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00.
In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe Hypophosphatasia (HPP). Our deep dive into the drug suggests the market is bigger vs. street expectations. We also updated our Soliris & expense assumptions to more accurately reflect company guidance. We believe incidence is greater than literature suggests & model 1/25,000 in US & 1/50,000 ex-US of severe pediatric HPP.”
Alexion Pharmaceuticals closed on Friday at $163.63.
Latest Ratings for ALXN
|Oct 2016||Brean Capital||Assumes||Buy|
|Sep 2016||Leerink Swann||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.